Cargando…
Biological Evaluation of Naproxen–Dehydrodipeptide Conjugates with Self-Hydrogelation Capacity as Dual LOX/COX Inhibitors
The use of peptide–drug conjugates is emerging as a powerful strategy for targeted drug delivery. Previously, we have found that peptides conjugated to a non-steroidal anti-inflammatory drug (NSAID), more specifically naproxen–dehydrodipeptide conjugates, readily form nanostructured fibrilar supramo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076388/ https://www.ncbi.nlm.nih.gov/pubmed/32028608 http://dx.doi.org/10.3390/pharmaceutics12020122 |
_version_ | 1783507205058723840 |
---|---|
author | Moreira, Rute Jervis, Peter J. Carvalho, André Ferreira, Paula M. T. Martins, José A. Valentão, Patrícia Andrade, Paula B. Pereira, David M. |
author_facet | Moreira, Rute Jervis, Peter J. Carvalho, André Ferreira, Paula M. T. Martins, José A. Valentão, Patrícia Andrade, Paula B. Pereira, David M. |
author_sort | Moreira, Rute |
collection | PubMed |
description | The use of peptide–drug conjugates is emerging as a powerful strategy for targeted drug delivery. Previously, we have found that peptides conjugated to a non-steroidal anti-inflammatory drug (NSAID), more specifically naproxen–dehydrodipeptide conjugates, readily form nanostructured fibrilar supramolecular hydrogels. These hydrogels were revealed as efficacious nano-carriers for drug delivery applications. Moreover, the incorporation of superparamagnetic iron oxide nanoparticles (SPIONs) rendered the hydrogels responsive to external magnetic fields, undergoing gel-to-solution phase transition upon remote magnetic excitation. Thus, magnetic dehydrodipeptide-based hydrogels may find interesting applications as responsive Magnetic Resonance Imaging (MRI) contrast agents and for magnetic hyperthermia-triggered drug-release applications. Supramolecular hydrogels where the hydrogelator molecule is endowed with intrinsic pharmacological properties can potentially fulfill a dual function in drug delivery systems as (passive) nanocariers for incorporated drugs and as active drugs themselves. In this present study, we investigated the pharmacological activities of a panel of naproxen–dehydrodipeptide conjugates, previously studied for their hydrogelation ability and as nanocarriers for drug-delivery applications. A focused library of dehydrodipeptides, containing N-terminal canonical amino acids (Phe, Tyr, Trp, Ala, Asp, Lys, Met) N-capped with naproxen and linked to a C-terminal dehydroaminoacid (ΔPhe, ΔAbu), were evaluated for their anti-inflammatory and anti-cancer activities, as well as for their cytotoxicity to non-cancer cells, using a variety of enzymatic and cellular assays. All compounds except one were able to significantly inhibit lipoxygenase (LOX) enzyme at a similar level to naproxen. One of the compounds 4 was able to inhibit the cyclooxygenase-2 (COX-2) to a greater extent than naproxen, without inhibiting cyclooxygenase-1 (COX-1), and therefore is a potential lead in the search for selective COX-2 inhibitors. This hydrogelator is a potential candidate for dual COX/LOX inhibition as an optimised strategy for treating inflammatory conditions. |
format | Online Article Text |
id | pubmed-7076388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70763882020-03-24 Biological Evaluation of Naproxen–Dehydrodipeptide Conjugates with Self-Hydrogelation Capacity as Dual LOX/COX Inhibitors Moreira, Rute Jervis, Peter J. Carvalho, André Ferreira, Paula M. T. Martins, José A. Valentão, Patrícia Andrade, Paula B. Pereira, David M. Pharmaceutics Article The use of peptide–drug conjugates is emerging as a powerful strategy for targeted drug delivery. Previously, we have found that peptides conjugated to a non-steroidal anti-inflammatory drug (NSAID), more specifically naproxen–dehydrodipeptide conjugates, readily form nanostructured fibrilar supramolecular hydrogels. These hydrogels were revealed as efficacious nano-carriers for drug delivery applications. Moreover, the incorporation of superparamagnetic iron oxide nanoparticles (SPIONs) rendered the hydrogels responsive to external magnetic fields, undergoing gel-to-solution phase transition upon remote magnetic excitation. Thus, magnetic dehydrodipeptide-based hydrogels may find interesting applications as responsive Magnetic Resonance Imaging (MRI) contrast agents and for magnetic hyperthermia-triggered drug-release applications. Supramolecular hydrogels where the hydrogelator molecule is endowed with intrinsic pharmacological properties can potentially fulfill a dual function in drug delivery systems as (passive) nanocariers for incorporated drugs and as active drugs themselves. In this present study, we investigated the pharmacological activities of a panel of naproxen–dehydrodipeptide conjugates, previously studied for their hydrogelation ability and as nanocarriers for drug-delivery applications. A focused library of dehydrodipeptides, containing N-terminal canonical amino acids (Phe, Tyr, Trp, Ala, Asp, Lys, Met) N-capped with naproxen and linked to a C-terminal dehydroaminoacid (ΔPhe, ΔAbu), were evaluated for their anti-inflammatory and anti-cancer activities, as well as for their cytotoxicity to non-cancer cells, using a variety of enzymatic and cellular assays. All compounds except one were able to significantly inhibit lipoxygenase (LOX) enzyme at a similar level to naproxen. One of the compounds 4 was able to inhibit the cyclooxygenase-2 (COX-2) to a greater extent than naproxen, without inhibiting cyclooxygenase-1 (COX-1), and therefore is a potential lead in the search for selective COX-2 inhibitors. This hydrogelator is a potential candidate for dual COX/LOX inhibition as an optimised strategy for treating inflammatory conditions. MDPI 2020-02-03 /pmc/articles/PMC7076388/ /pubmed/32028608 http://dx.doi.org/10.3390/pharmaceutics12020122 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Moreira, Rute Jervis, Peter J. Carvalho, André Ferreira, Paula M. T. Martins, José A. Valentão, Patrícia Andrade, Paula B. Pereira, David M. Biological Evaluation of Naproxen–Dehydrodipeptide Conjugates with Self-Hydrogelation Capacity as Dual LOX/COX Inhibitors |
title | Biological Evaluation of Naproxen–Dehydrodipeptide Conjugates with Self-Hydrogelation Capacity as Dual LOX/COX Inhibitors |
title_full | Biological Evaluation of Naproxen–Dehydrodipeptide Conjugates with Self-Hydrogelation Capacity as Dual LOX/COX Inhibitors |
title_fullStr | Biological Evaluation of Naproxen–Dehydrodipeptide Conjugates with Self-Hydrogelation Capacity as Dual LOX/COX Inhibitors |
title_full_unstemmed | Biological Evaluation of Naproxen–Dehydrodipeptide Conjugates with Self-Hydrogelation Capacity as Dual LOX/COX Inhibitors |
title_short | Biological Evaluation of Naproxen–Dehydrodipeptide Conjugates with Self-Hydrogelation Capacity as Dual LOX/COX Inhibitors |
title_sort | biological evaluation of naproxen–dehydrodipeptide conjugates with self-hydrogelation capacity as dual lox/cox inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076388/ https://www.ncbi.nlm.nih.gov/pubmed/32028608 http://dx.doi.org/10.3390/pharmaceutics12020122 |
work_keys_str_mv | AT moreirarute biologicalevaluationofnaproxendehydrodipeptideconjugateswithselfhydrogelationcapacityasdualloxcoxinhibitors AT jervispeterj biologicalevaluationofnaproxendehydrodipeptideconjugateswithselfhydrogelationcapacityasdualloxcoxinhibitors AT carvalhoandre biologicalevaluationofnaproxendehydrodipeptideconjugateswithselfhydrogelationcapacityasdualloxcoxinhibitors AT ferreirapaulamt biologicalevaluationofnaproxendehydrodipeptideconjugateswithselfhydrogelationcapacityasdualloxcoxinhibitors AT martinsjosea biologicalevaluationofnaproxendehydrodipeptideconjugateswithselfhydrogelationcapacityasdualloxcoxinhibitors AT valentaopatricia biologicalevaluationofnaproxendehydrodipeptideconjugateswithselfhydrogelationcapacityasdualloxcoxinhibitors AT andradepaulab biologicalevaluationofnaproxendehydrodipeptideconjugateswithselfhydrogelationcapacityasdualloxcoxinhibitors AT pereiradavidm biologicalevaluationofnaproxendehydrodipeptideconjugateswithselfhydrogelationcapacityasdualloxcoxinhibitors |